FINANCINGS

Adalta Ltd. is looking to raise up to $7.55 million in an IPO on the Australian Securities Exchange.

Audentes Therapeutics Inc. plans to raise $75 million by offering 5 million shares at a price range of $14 to $16 in its IPO.

Azurrx Biopharma Inc. filed with the SEC for an IPO seeking to raise up to $15 million.

Galena Biopharma Inc. entered securities purchase agreements with certain institutional investors in a concurrent private placement, resulting in gross proceeds of $12.6 million.

GW Pharma plc has raised $252 million in an oversubscribed public offering.

Kadmon Holdings LLC set terms for its IPO, seeking to raise $100 million by offering 5.6 million shares priced in a range of $16 to $20.

Motif Bio plc filed a registration statement with the SEC seeking to raise up to $40 million in a U.S. IPO of American depositary shares.

Protagonist Therapeutics Inc. filed to raise up to $75 million in an IPO, and would list on Nasdaq under the symbol PTGX.

Sapience Therapeutics Inc. raised $22.5 million in a series A financing.

Tesaro Inc. closed its underwritten public offering of common stock for estimated net proceeds of approximately $409 million.

Valneva SE said the European Investment Bank granted it a $27.6 million loan facility to support its vaccine R&D activities.

DEALS

Amgen Inc. and Daiichi Sankyo Co. Ltd. said they inked an exclusive agreement to commercialize nine biosimilars in Japan.

Bayer AG and X-Chem Inc. expanded their global drug discovery collaboration to encompass the entire bandwidth of therapeutic areas and target classes from Bayer's R&D pipeline.

Bioaffinity Technologies Inc. has renewed its collaboration with the University of Texas Health Science Center at San Antonio to conduct R&D of cancer diagnostic and therapeutic agents using the company's porphyrin-based technology platform.

C4X Discovery Holdings plc has acquired a suite of drug discovery technologies from Molplex Ltd. comprising a software-based system that combines chemo-informatics, computational chemistry and artificial intelligence to optimize the drug development process.

Cell Medica Ltd. acquired Delenex Therapeutics AG to accelerate the development of its gene-modified immune cell products to treat cancer.

Celyad SA signed a $311.5 million plus royalties deal with Ono Pharmaceutical Co Ltd. for the development and commercialization of a preclinical-stage allogeneic T-cell immunotherapy.

Cantabio Pharmaceuticals Inc. signed an agreement with Purdue Research Foundation to advance work on targeting DJ-1 protein small-molecule chaperone drug candidates for the treatment of Parkinson's disease and other related neurodegenerative diseases.

Evelo Biosciences Inc. and Epiva Biosciences Inc., portfolio companies of Flagship Ventures, have merged to create an immuno-microbiome company under the Evelo name.

Ligand Pharmaceuticals Inc. is licensing its Omnirat, Omnimouse and Omniflic platforms to Gilead Sciences Inc. for use in discovering fully human mono- and bispecific antibodies.

Roivant Sciences Ltd. and Plexcera Therapeutics LLC formed Enzyvant Sciences Ltd. to develop recombinant human acid ceramidase, an enzyme replacement therapy to treat patients with Farber disease.

Sorrento Therapeutics Inc. inked an agreement with Les Laboratoires Servier SAS for its fully human anti-PD-1 monoclonal antibody, STI-A1110.

. . . AND MORE

Abbvie Inc. said the FDA granted rare pediatric disease designation for ABT-414, an investigational antibody drug-conjugate targeting EGFR for the treatment of pediatric patients with EGFR-amplified diffuse intrinsic pontine glioma.

Delmar Pharmaceuticals Inc. received approval from Nasdaq to list its common stock, which will trade under the ticker symbol DMPI.

Medicure Inc. received an FDA complete response letter for its supplemental new drug application requesting an expanded indication for Aggrastat (tirofiban hydrochloride) in the treatment of patients presenting with ST segment elevation myocardial infarction.

Oncternal Therapeutics Inc. said the FDA granted orphan drug designation to TK216, its small molecule that inhibits Ets-family transcription factor oncoproteins, to treat Ewing sarcoma.

Orexigen Therapeutics Inc. has made a 1-for-10 reverse stock split of all of the outstanding shares of its common stock.

Shire plc said the FDA approved Xiidra (lifitegrast ophthalmic solution) 5 percent, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.

The CEOs of Astrazeneca plc and Glaxosmithkline plc are to head an industry-government task force formed to set out priorities for life sciences in the negotiations for the U.K. leaving the EU.

The FDA's Arthritis Advisory Committee (AAC) voted 26-0 to support the licensure of Amgen Inc.'s Humira biosimilar and 20-0 in support of Sandoz Inc.'s GP2015 as a biosimilar to Amgen's Enbrel (etanercept).